Global Leukapheresis Market is Expected to Reach USD 561.6 Million by 2031: Allied Market Research
Allied Market Research
Allied Market Research

Increase in the prevalence of chronic diseases such as leukemia, a rise in the number of clinical trials and public & private investments for the development of CAR (chimeric antigen receptor)-T therapy, and rise in government initiatives that promote blood donations in developing countries drive the growth of the global leukapheresis market. Region-wise, North America is likely to maintain its dominance during the forecast period.

Portland, OR, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Leukapheresis Market generated $245.7 million in 2021, and is estimated to reach $561.6 million by 2031, witnessing a CAGR of 8.6% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscape, and competitive scenario. The report is a helpful source of information for leading market players, new entrants, investors, and stakeholders in devising strategies for the future and taking steps to strengthen their position in the market.

Download Free Sample Report (274 Pages PDF with Insights, Charts, Tables, Figures): https://www.alliedmarketresearch.com/request-sample/9449

Report coverage & details:

Report Coverage

Details

Forecast Period

2022­–2031

Market Size in 2031

$561.6 Million

CAGR

8.6%

No. of Pages in Report

274

Segments Covered

Product, Method, Application, End User, and Region

Drivers

Increase in prevalence of chronic diseases such as leukemia

Increase in the number of clinical trials and increase in public & private investments for the development of CAR (chimeric antigen receptor)-T therapy where leukapheresis is the first step

Rise in the number of major players that deal with leukapheresis

Surge in government initiatives promoting blood donations in developing countries such as China and India

Opportunities

Increase in demand for leukapheresis in pediatric patients

Restraints



High cost associated with leukapheresis therapeutics


Covid-19 Scenario:

  • The COVID-19 had a positive impact on the growth of the global leukapheresis market, as the vaccines which were undergoing clinical testing included research on white blood cells. This research played a crucial role in the creation of new vaccinations.

  • Moreover, research was carried out to determine how the COVID-19 affects white blood cells. For instance, to comprehend how SARS-CoV-2 affects lymphocytes, the NIH (National Institute of Health) performed clinical trials that called for leukapheresis.

  • Furthermore, the regularization of the supply chain of medications by key players and the rise in the number of patient visits for investigation and treatment fuelled the growth of the leukapheresis market in the post-pandemic period.